Virax Biolabs (VRAX) Common Equity (2021 - 2026)
Virax Biolabs (VRAX) posted quarterly Common Equity of $7.3 million for Q1 2026, up 28.77% year-over-year from $5.7 million in Q1 2025, and up 28.77% quarter-over-quarter from $5.7 million in Q1 2025.
Virax Biolabs (VRAX) Common Equity (2021 - 2026) Analysis & Trends
Virax Biolabs' Common Equity history runs 6 years deep, the most recent figure standing at $7.3 million for Q1 2026.
- In Q1 2026, Common Equity rose 28.77% year-over-year to $7.3 million; the TTM figure through Mar 2026 stood at $7.3 million (up 28.77% YoY), while the FY2026 annual figure was $7.3 million, up 28.77% from the prior year.
- Common Equity for Q1 2026 stood at $7.3 million, up from $5.7 million in the prior quarter.
- The five-year high for Common Equity was $8.9 million in Q1 2023, with the low at -$1.2 million in Q1 2022.
- The 5-year median for Common Equity is $5.7 million (2025), against an average of $5.2 million.
- The sharpest annual moves came in 2022 and 2023: Common Equity slumped 43.87% in 2022, then soared 844.04% in 2023.
- Virax Biolabs' Common Equity stood at -$1.2 million in 2022, then jumped by 844.04% to $8.9 million in 2023, then slumped by 42.29% to $5.1 million in 2024, then increased by 10.85% to $5.7 million in 2025, then grew by 28.77% to $7.3 million in 2026.
- Business Quant data shows VRAX's Common Equity at $7.3 million in Q1 2026, $5.7 million in Q1 2025, and $5.1 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Virax Biolabs | 1.31 Mn | -5.13 Mn | - | 7.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.33 Mn |
| Mar 31, 2025 | 5.70 Mn |
| Mar 31, 2024 | 5.14 Mn |
| Mar 31, 2023 | 8.90 Mn |
| Mar 31, 2022 | -1.20 Mn |
| Mar 31, 2021 | -831,814.00 |